ArticleAnnals of surgical oncology2025
The Use of Radar-Guided Localization to Identify Metastatic Melanoma After Neoadjuvant Immunotherapy.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadar-guided localization (RGL) is a nonradioactive, wireless technique used to localize target lesions for resection via a percutaneously placed intra-tumoral reflector and a handheld probe intraoperatively. RGL plays a critical role in the setting of nonpalpable lesions. This study describes RGL for patients undergoing neoadjuvant immunotherapy (NEO) for metastatic melanoma.
methodsA retrospective review included stage III-IV melanoma patients who underwent NEO followed by metastasectomy with RGL.
resultsTwenty-three patients were identified. Median age was 65 years; ten were female. Twenty patients had a radiographic response to NEO in the target lesion, and three demonstrated progression on NEO. Fourteen lesions were palpable prior to NEO, and five (36%) remained palpable after NEO. Reflectors were successfully retrieved in all 23 patients at a median of 99 (range 1-282) days after RGL placement. Operations included 18 targeted index lymph node dissections, two complete therapeutic lymph node dissections, and three subcutaneous/soft tissue nodule resections. Nineteen patients had a major pathologic response to NEO (0 to <10% viable tumor), one patient had a partial response (10-50% viable tumor), and three patients had a pathologic nonresponse (>50% viable tumor).
conclusionsIn this series of RGL and resection of metastatic melanoma after NEO, two-thirds of the index lesions became nonpalpable after NEO, and RGL allowed for accurate intraoperative identification and retrieval at any interval (days to months). Specific target lesion marking with fiducial markers for intraoperative identification and targeted resection allows the treating team to examine pathologic response and dictate further therapy on an individualized basis.
Indexed as
Identifiers
40279056What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.